This website serves as a source of news and information for the residents of Bridgewater, Bound Brook, and surrounding communities regarding the remedy and restoration of the American Cyanamid Superfund Site owned by Wyeth Holdings LLC (WH). Pfizer Inc assumed responsibility for the site on October 15, 2009, through its larger acquisition of Wyeth. Although Pfizer never operated at the site, Pfizer takes its responsibility seriously and is aggressively working to improve site conditions.
Under the oversight of the U.S. Environmental Protection Agency (USEPA) and the New Jersey Department of Environmental Protection (NJDEP), Pfizer is working to accomplish four key objectives:
- To implement a remediation program that is protective of human health and the environment;
- To ensure that site remediation activities facilitate reuse and redevelopment of portions of the property;
- To preserve and enhance the ecological assets of the property in a manner that creates value in the Raritan River regional ecosystem; and
- To position the property as an asset to the local community and the region.
On September 28, 2018, the U.S. Environmental Protection Agency (USEPA) issued a Record of Decision for Operable Unit 8, commonly referred to as Impoundments 1 and 2, at the American Cyanamid Superfund Site located in Bridgewater and Bound Brook, New Jersey. The Record of Decision and Response to Public Comments document is available to the public at https://semspub.epa.gov/work/02/550185.pdf.
WH is working under a Consent Decree with the U.S. Environmental Protection Agency (USEPA) to implement the site-wide remedy at the American Cyanamid Superfund Site. Under this agreement, WH is moving forward with the remedy of site soils, site groundwater, and a majority of the remaining impoundments still requiring remediation, as described in the Record of Decision issued by USEPA on September 27, 2012.
The WH team has invested significant resources in the engineering and design of this remediation program. Construction of the groundwater control, extraction, treatment, and reinjection system began in early 2017 and is nearly complete. Visit the Current Activities page to view photos of recent construction activities on the site.
Pfizer continues to actively work with USEPA, NJDEP, and other stakeholders, to move the site remediation process forward. We are committed to implementing a site restoration program that is responsive to stakeholder input and returns the property to productive use. Additional details regarding the status of the site and recent activities can be found on the Site Progress page.